NCT00622258 is a Phase 1 clinical trial of Everolmus in Non-Hodgkin's Lymphoma, sponsored by Novartis Pharmaceuticals.

Who is sponsoring NCT00622258?

NCT00622258 is sponsored by Novartis Pharmaceuticals.

What drugs are being tested in NCT00622258?

Interventions in NCT00622258: Everolmus.

What condition does NCT00622258 study?

NCT00622258 studies Non-Hodgkin's Lymphoma.

Is NCT00622258 still recruiting?

NCT00622258 is currently completed. Last updated 17 December 2020.

Last reviewed 2020-12-17 · How we verify

NCT00622258

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase I Dose Escalation Study of RAD001 Administered in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Completed Phase 1 Last updated 17 December 2020

What this trial tests

Phase 1 trial testing Everolmus in Non-Hodgkin's Lymphoma in 13 participants. Completed in 1 January 2014.

Timeline

1 March 2008

Primary endpoint
1 January 2014

1 January 2014

Quick facts

Lead sponsor	Novartis Pharmaceuticals
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	13
Start date	1 March 2008
Primary completion	1 January 2014
Estimated completion	1 January 2014
Sites	8 locations across Japan

Drugs / interventions tested

Everolmus — full drug profile →

Conditions studied

Non-Hodgkin's Lymphoma — all drugs for Non-Hodgkin's Lymphoma →

Sponsor

Novartis Pharmaceuticals — full company profile →

Who can join

20 and older, any sex, with Non-Hodgkin's Lymphoma. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

To assess the safety and tolerability of RAD001 in Japanese patients with relapsed or refractory non-Hodgkin's lymphoma
Time frame: whole study period
To assess the pharmacokinetics in Japanese patients
Time frame: 1st sycle

Sponsor's own description

This study assesses the tolerability, safety, efficacy and pharmacokinetics of everolimus in Japanese patients. Everolimus is administered orally everyday to adult patients with relapsed or refractory non-Hodgkin's lymphoma who have progressed despite standard therapy or for whom standard systemic therapy dose not exist.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

VISTA: A Mediator of Quiescence and a Promising Target in Cancer Immunotherapy.
Yuan L, Tatineni J, Mahoney KM, Freeman GJ. · · 2021 · cited 173× · PMID 33495077 · DOI 10.1016/j.it.2020.12.008
Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies.
Teachey DT, Grupp SA, Brown VI. · · 2009 · cited 87× · PMID 19344392 · DOI 10.1111/j.1365-2141.2009.07657.x
Oncogenic Signaling Pathways and Pathway-Based Therapeutic Biomarkers in Lymphoid Malignancies.
Sun R, Wang J, Young KH. · · 2017 · cited 4× · PMID 29604930 · DOI 10.1615/critrevoncog.2017020816

Verify or expand the search:

Other recruiting trials for Non-Hodgkin's Lymphoma

Currently open trials in the same condition.

NCT07202052 — Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT) · Phase 2, PHASE3 · recruiting
NCT06208735 — CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies · Phase 1 · recruiting
NCT06343311 — T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) · Phase 1, PHASE2 · recruiting
NCT05884333 — Cord Blood Transplant in Adults With Blood Cancers · Phase 2 · recruiting
NCT04532203 — A Study of CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Central Nervous System Hematological Maligna · EARLY_PHASE1 · recruiting

Other Novartis Pharmaceuticals trials

Trials by the same sponsor.

NCT07498335 — Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary · Phase 3 · not yet recruiting
NCT07489573 — Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa · Phase 4 · not yet recruiting
NCT07484269 — PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan · not yet recruiting
NCT07416162 — A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy · not yet recruiting
NCT07387926 — Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+ · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00622258 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Novartis Pharmaceuticals
Last refreshed: 17 December 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00622258.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing